Werewolf Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Werewolf Therapeutics, Inc. carries a market capitalization of 46.96M, placing it among publicly traded companies globally. Its enterprise value stands at -4.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 46.96M |
| Enterprise Value | -4.50M |
Share Statistics
Werewolf Therapeutics, Inc. currently has 48.60M shares outstanding.
| Shares Outstanding | 48.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.82, and the price-to-book ratio stands at 1.07.
| PE Ratio | N/A |
| PS Ratio | 0.82 |
| PB Ratio | 1.07 |
| P/TBV Ratio | 1.07 |
| P/FCF Ratio | -0.58 |
| P/OCF Ratio | -0.57 |
Financial Position
Werewolf Therapeutics, Inc. maintains a current ratio of 2.91, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.91 |
| Quick Ratio | 2.80 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -6.06 |
Financial Efficiency
| Return on Equity (ROE) | -119.86 |
| Return on Assets (ROA) | -59.31 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -38.33 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Werewolf Therapeutics, Inc.'s stock has declined approximately -28.42222% over the past 52 weeks. The 50-day moving average sits at 0.49, while the 200-day moving average is 0.65.
| Beta (5Y) | N/A |
| 52-Week Price Change | -28.42222% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.65 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Werewolf Therapeutics, Inc. generated 21.00M in revenue and converted that into -34.61M in net income, yielding earnings per share of -0.72. EBITDA reached -27.60M, while operating income came in at -31.26M.
| Revenue | 21.00M |
| Gross Profit | N/A |
| Operating Income | -31.26M |
| Pretax Income | -34.61M |
| Net Income | -34.61M |
| EBITDA | -27.60M |
| EBIT | -31.26M |
| Earnings Per Share (EPS) | -0.72 |
Balance Sheet
Total book value stands at 16.29M, with working capital of 15.03M providing operational flexibility.
| Cash & Cash Equivalents | 21.99M |
| Total Debt | N/A |
| Net Debt | -21.99M |
| Equity (Book Value) | 16.29M |
| Book Value Per Share | 0.34 |
| Working Capital | 15.03M |
Cash Flow
Werewolf Therapeutics, Inc. produced -30.15M in operating cash flow over the past twelve months.
| Operating Cash Flow | -30.15M |
| Capital Expenditures | N/A |
| Free Cash Flow | -30.15M |
| FCF Per Share | -0.63 |
Margins
Werewolf Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -148.84 and net profit margin of -164.82 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -148.84 |
| Pretax Margin | -164.82 |
| Profit Margin | -164.82 |
| EBITDA Margin | -131.45 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -32.25 |
| FCF Yield | -173.61 |
Scores
Werewolf Therapeutics, Inc. posts an Altman Z-Score of -29.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -29.45 |